INTRODUCTION

Intraductal papillary mucinous neoplasm of the bile duct (IPMN-B) is a rare but increasingly diagnosed clinical entity. The lesion is a bile duct tumor with a macroscopic papillary appearance and visible mucin secretion. It is considered a biliary variant of intraductal papillary mucinous neoplasm of the pancreas (IPMN-P) which is composed of numerous papillary fronds with fine fibrovascular cores.¹

This clinical entity is a precursor of invasive carcinoma, and 40-80% of resected IPMN-Bs contain invasive components.² Therefore, most cases are treated surgically. However, conservative therapy was considered for inoperable patients with complication, old age and performance status. Recently, local ablation therapy has been proposed as an alternative palliative or curative treatment for tumors with intermediate malignant characteris-
tics, but its role in the management of IPMN-B has not been completely investigated. We report a rare case of an IPMN-B successfully treated with argon plasma coagulation (APC).

CASE

The patient is a 75-year old woman who was admitted due to epigastric pain. She had undergone percutaneous transhepatic cholangioscopy (PTCS) with electrohydraulic lithotripsy 8 years before to remove a common bile duct stone and intrahepatic duct (IHD) stones. During this admission, the results of biochemical tests were unremarkable. Contrast-enhanced abdominal and pelvic computed tomography (CT) revealed IHD dilatation accompanied by multiple stones of right IHD and mural nodules of left IHD. The mural nodules exhibited isodense and hyperdense attenuation during the late arterial phase and isodense attenuation during the portal-venous and delayed phases (Fig. 1). Magnetic resonance image (MRI) showed marked dilatation of the left intrahepatic duct and bile duct in the T2-weighted image (WI). There were linear filling defect lesions of bile duct at 60 minutes delay in the T1-WI. The lesions

Fig. 1. Contrast-enhanced abdominal and pelvic computed tomography scan reveals intrahepatic duct dilatation due to intrahepatic ductal mural nodule (intraductal papillary mucinous neoplasm of the bile duct) (black arrow).

Fig. 2. (A) Magnetic resonance image shows dilation of intrahepatic duct tract and intraductal papillary mucinous neoplasm of the bile duct (white arrow). (B) Dilatation of the left intrahepatic duct and bile duct in T2WI shows excretion of contrast media (white arrow). (C) There are linear filling defect lesions of bile duct (white arrow) at 60 minutes delay in T1WI. WI, weighted image.
were mucin secretions of mural nodules. These findings suggested a diagnosis of a left intrahepatic IPMN-B (Fig. 2).

Because of given her old age and Eastern Cooperative Oncology Group score 3, we recommended conservative management instead of surgical treatment. She chose APC ablation therapy under the information of various treatment options. Percutaneous transhepatic biliary drainage was performed, and the transhepatic tract was sequentially dilated by introducing transhepatic plastic dilators of increasing diameter (up to 18 Fr). IHD stones were then removed by PTCS (CYF-VA2, Olympus Optical Co., Tokyo, Japan), and the intrahepatic papillary lesion was simultaneously biopsied. The histopathological diagnosis of low-grade IPMN was thereby confirmed (Fig. 3).

A lot of mucin and intraductal papillary projection were shown in main left IHD. Two sessions of APC ablation therapy were subsequently performed to reduce mucin production (Fig. 4). Subsequently APC ablation was repeatedly per-

![Fig. 3. Left intrahepatic bile duct biopsy shows papillae with fibrovascular core was lined with dysplastic biliary epithelium of low grade (H&E, ×400).](image)

![Fig. 4. (A-E) Percutaneous transhepatic cholangioscopy and (F, G) cholangiography. (A, B) The intraductal mucins and papillary projections were seen in left main intrahepatic duct. (C) The lesion should be located at the direction of 7 o’clock during the procedure. (D, E) The argon plasma coagulation was repeatedly applied until the whitish tumor mass was not seen grossly. (F) The cholangiography showed no contrast filling in left intrahepatic duct and (G) filling after procedure.](image)
formed until the white tumor tissue was not visible with the naked eye. However, the patient could not tolerate the procedure for a prolonged duration owing to her age, the procedure was conducted over 2 sessions. We used a VIO 300D system (ERBE, Marietta, GA, USA) in forced APC mode at a gas flow/power setting of 1.0L/min and 30 watts in conjunction with a Straight Fire probe (FiAPC probe 2200A, Ø2.3 mm, flexible, length 2.2 m) (ERBE, Marietta, GA, USA).

One month later, the patient underwent follow-up PTCS with a forceps biopsy that was negative for malignancy (Fig. 5). Four months later, a follow-up contrast-enhanced abdominal and pelvic CT showed no definite lesion of the mural nodule and markedly decreased both IHD dilatation compared with previous image findings (Fig. 6). But, left IHD presented a slight dilatation due to suspected benign stricture without definite mass lesion. Currently, the patient is asymptomatic and in good clinical condition. The disease is stable, and she is regularly observed on an outpatient basis.

**DISCUSSION**

IPMN-B is characterized by predominantly intraductal papillary growth and may be located anywhere along the biliary tree. It can display any degree of pathological transformation from low-grade dysplasia to invasive carcinoma. In the past, such growths were identified by various names such as biliary papillomatosis, mucin-producing cholangiocarcinoma, mucin-hypersecreting bile duct tumor, and biliary intraductal papillary mucinous neoplasm. The term IPMN-B was adopted in the 2010 World Health Organization classification as a distinct clinical and pathologic entity.

IPMN-B is mainly found in eastern Asian locations such as Taiwan, Japan, and Korea, where hepatolithiasis and clonorchiasis are endemic. Papillary cholangiocarcinoma accounts for approximately 4–38% of all bile duct adenocarcinomas. The most common presenting symptom is abdominal pain, probably due to biliary stones, cholangitis, or high pressure in the biliary tract causing mucin hypersecretion. Wang et al. reported that the process of inflammatory stimulation due to biliary stones may play a role in the development of IPMN-B.

Radiologic (e.g., ultrasonography, CT, MRI) findings of
IPMN-B include bile duct dilatation and intraductal masses. Direct cholangiography (e.g., endoscopic retrograde cholangiography) is useful for the detection of mucobilia, which is seen in nearly one-third of patients with IPMN-B, evidenced by diffuse dilatation of the bile duct with an amorphous filling defect. Cholangioscopy, including PTCS and peroral cholangioscopy, can be used to approach the bile duct directly, confirm the histology, and assess the extent of the tumor, including superficial spreading along the biliary epithelium, which provides information that can be used to choose the appropriate treatment.6

In this patient, contrast-enhanced abdominal and pelvic CT was performed because the patient was experiencing epigastric pain, and IHD dilatation accompanied by IHD stones and possible cholangiocarcinoma were revealed. MRI, performed in preparation for IHD stone removal, identified a multifocal mural nodule suspicious for IPMN-B. This diagnosis was confirmed by PTCS biopsy.

IPMN-B may behave more aggressively than IPMN-P. Recently, Sclabas et al.9 suggested that based on mucin glycoprotein (MUC) expression patterns (high frequency of MUC1 expression and/or absence of MUC2 expression), IPMN-B displays similarities to main duct IPMN-P, which is more aggressive than branch duct IPMN-P.10

The risk factors for a potentially malignant IPMN-P include main duct IPMN-P, male sex, advanced age, tumor size >2 cm, mural nodes in the cyst, symptoms, distension of the pancreatic duct or bile duct, enlarged lymph nodes, positive cytology, and carcinoembryonic antigen >200 ng/mL in the cyst’s contents.11 Because of the significant risk of malignancy, surgical resection is the treatment of choice for IPMN-P.

IPMN-B in common with IPMN-P should be removed sur-

**Table 1.** Previously reported palliative therapies for intraductal papillary mucinous neoplasm of the bile duct

| Treatment                      | Procedure                                                                                                                                                                                                 | Mechanism                                                                                           | Benefits                                                                                      | Limitations                                                                                           |
|--------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| Radiofrequency ablation (RFA)  | Propagation of heat energy using electrode and RF generator  
  - Electrode : a unique design featuring 7 mm total length with two 0.8 mm diameter holes located 5 mm from the tip  
  - RF generator : modulation by an automatic power control unit | Sustained thermal damage to the epithelium, resulting in destruction of the inner epithelial lining of the cyst | Effective for small to medium-sized tumors with fewer complications | For larger lesion, an increased risk of residual and recurrence                                      |
| Laser ablation                 | Holmium laser fulguration (8 W) to the lesion                                                                                                                                                             | Destruction and removal of tumor using a high-frequency electric current applied with a needle-like electrode | Minimally invasive, quick and easy treatment option | Relatively high cost of the laser equipment  
  Lack of tissue for histology  
  Risk of recurrence |
| Photodynamic therapy (PDT)     | Delivery of light to the target area using endoscopes and fiberoptic catheters after administering photosensitizers intravenously  
  - Penetration depth of 5-6 mm, depending on the physical attributes of the surrounding tissue (particle scatter, light absorption, etc.) | Producing localized tissue necrosis with light (most conveniently from a laser) after prior administration of a photosensitizer in the presence of oxygen | Simpler and a shorter recovery time than any form of treatment  
  Relatively low incidence of serious treatment related complications | Causing some necrosis in adjacent normal tissue  
  where normal and neoplastic tissue meet  
  Cutaneous photosensitivity  
  Relatively high cost  
  Risk of recurrence |
| Argon plasma coagulation (APC) | Using argon gas to deliver plasma of evenly distributed thermal energy to a field of tissue adjacent to the probe  
  - Penetration depth of 2-3 mm | Coagulating tissue which employs a high frequency electric current and ionised argon gas | Ability to treat large surface and superficial depth quickly  
  Ease of application, speedy treatment of multiple lesions  
  Relatively lower cost | Risk of recurrence |
IPMN-B Treated with APC

Several options are available for the treatment of inoperable IPMN-B. To date, no clinical trials on these treatments have been published except for some case reports. To date, most cases of IPMN-B are treated surgically. In our patient’s case, surgery was not a viable option. APC ablation therapy is known to treat large surface areas relatively quickly. In this case, it was recommended to reduce mucus production and thereby decrease the size of the dilated duct. Brauer et al. reported a case of IPMN-B treated with APC ablation therapy that was not successful; the patient died of refractory hepatic encephalopathy one month later. In this case, the patient is asymptomatic and in good clinical conditions eight months after diagnosis.

Our findings suggest that APC could be used as an alternative treatment for some patients with inoperable IPMN-B.

REFERENCES

1. D’Souza MA, Isaksson B, Löhr M, et al. The clinicopathological spectrum and management of intraductal papillary mucinous neoplasm of the bile duct (IPMN-B). Scand J Gastroenterol 2013;48:473-479.
2. Wang X, Cai YQ, Chen YH, Liu XB. Biliary tract intraductal papillary mucinous neoplasm: Report of 19 cases. World J Gastroenterol 2015;21:4261-4267.
3. Nakanuma Y, Curado MP, Franceschi S, et al. Intrahepatic cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban R, Theise N, eds. WHO classification of tumours of the digestive system, 4th ed. p217, Lyon, IARC, 2010.
4. Terada T. Non-invasive intraductal papillary neoplasms of the common bile duct: a clinicopathologic study of six cases. Int J Clin Exp Pathol 2012;5:690-697.
5. Rocha FG, Lee H, Katabi N, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012;56:1352-1360.
6. Wan XS, Xu YY, Qian JY, et al. Intraductal papillary neoplasm of the bile duct. World J Gastroenterol 2013;19:8595-8604.
7. Tsuyuguchi T, Sakai Y, Sugiyama H, et al. Endoscopic diagnosis of intraductal papillary mucinous neoplasm of the bile duct. J Hepatobiliary Pancreat Sci 2010;17:230-235.
8. Tsou YK, Liu NJ, Wu RC, et al. Endoscopic retrograde cholangiography in the diagnosis and treatment of mucobilia. Scand J Gastroenterol 2008;43:1137-1144.
9. Sclabas GM, Barton JG, Smyrk TC, et al. Frequency of subtypes of biliary intraductal papillary mucinous neoplasm and their MUC1, MUC2, and DPC4 expression patterns differ from pancreatic intraductal papillary mucinous neoplasm. J Am Coll Surg 2012;214:27-32.
10. Minagawa N, Sato N, Mori Y, Tamura T, Higure A, Yamaguchi K. A comparison between intraductal papillary neoplasms of the biliary tract and pancreatic intraductal papillary mucinous neoplasms.
tract (BTIPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes. Eur J Surg Oncol 2013;39:554-558.

11. Grützmann R, Post S, Saeger HD, Niedergethmann M. Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis. Dtsch Arztebl Int 2011;108:788-794.

12. Park JS, Seo DW, Song TJ, et al. Endoscopic ultrasound-guided ablation of branch-duct intraductal papillary mucinous neoplasms: feasibility and safety tests using porcine gallbladders. Dig Endosc 2016;28:599-606.

13. Baughman SM, Bishoff JT, Zimmerman MK, Carter MR, Kerby JD, Watkins KT. Case report: serial percutaneous cholangioscopy with laser ablation for the management of locally recurrent biliary intraductal papillary mucinous tumor. J Gastrointest Surg 2005;9:215-218.

14. Topazian M, Zhong N, Baron TH, Vege SS, Wang KK. Photodynamic therapy of intraductal papillary mucinous neoplasm. Endoscopy 2012;44:213-215.

15. Brauer BC, Fukami N, Chen YK. Direct cholangioscopy with narrow-band imaging, chromoendoscopy, and argon plasma coagulation of intraductal papillary mucinous neoplasm of the bile duct (with videos). Gastrointest Endosc 2008;67:574-576.